This plant is MN Pharmaceuticals' newest production facility, it was completed at the beginning of 2009. The plant is dedicated to the production of sterile oncolytic products.
Plant IV has been awarded the Environment Management System Certificate in the scope of ISO 14001 Standards by the British Management Systems Organization BSI in December 2008. In April 2009, this plant has been awarded the OHSAS 18001 Occupational Health and Safety Certificate which was presented by the British Management Systems Organization BSI.
The Oncolytic Products Plant was approved by the US Food and Drug Administration (FDA) in May 2010 and by the European Medicine Agency (EMEA) in July 2010.
In Plant IV, products in pharmaceutical dosage forms such as liquid vials for injection and freeze-dried vials for injection are manufactured.